NIH awards Baylor more than $15 million to fund two rare diseases consortia
The funding is to renew the Brittle Bone Disorders Consortium for five years and to launch the Rare Organic Acidemias Research Consortium.
Read More
The funding is to renew the Brittle Bone Disorders Consortium for five years and to launch the Rare Organic Acidemias Research Consortium.
Read MoreHow Texas Children’s Hospital and Baylor are using exome sequencing to level the playing field for patients with undiagnosed rare diseases.
Read MoreDr. James R. Lupski has delivered more than 620 lectures in 37 countries, but none was received with nearly the same enthusiasm as his Mendel lecture this past June in Berlin.
Read MoreAIM narrows the differential genetic diagnoses down to a few genes and can potentially guide the discovery of previously unknown disorders.
Read MoreThis new testing method represents a paradigm shift in laboratory genetics, moving from the traditional DNA-centric approach to one focusing on the patient’s cells.
Read MoreDespite the advancement of clinical genetic tests to diagnose rare diseases and the benefits of identifying a genetic diagnosis for pediatric patients and their families,
Read MoreThe work also highlights the value of human organoid technology to improve the understanding of any disease and identify potential clinical applications.
Read MoreBaylor College of Medicine has formed a new center to evaluate patients with rare genetic conditions.
Read More“Genomics of Rare Diseases” offers readers a broad understanding of current knowledge on rare diseases from a genomics perspective.
Read MoreDr. Juan Botas shared his challenging beginnings, his passion for neuroscience and how he is bringing science to a general audience.
Read More